Status:

TERMINATED

Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)

Lead Sponsor:

Indiana University

Conditions:

Renal Malignant Tumor

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Patients with renal lesions suspicious for renal cell carcinoma (RCC) have a variety of different treatment pathways available to them. Imaging surveillance is being used frequently on smaller renal m...

Detailed Description

Renal malignancies are relatively common, with lifetime risk ranging from 1 in 48 in men to 1 in 83 in women, of which RCC is the most common. RCC comes in a variety of subtypes, and pathologic grade ...

Eligibility Criteria

Inclusion

  • Greater than or equal to 18 years of age
  • Previously identified renal mass with radiology and clinical features consistent with RCC
  • Clinical care plan includes partial or total nephrectomy

Exclusion

  • Less than 18 years of age
  • Currently pregnant
  • Renal mass with clinical care plan that does not include nephrectomy
  • Renal mass suspected to be non RCC neoplasm by imaging and clinical data
  • Renal mass unable to be visualized by grayscale ultrasound
  • Known renal vein thrombosis

Key Trial Info

Start Date :

July 16 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 21 2021

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT03821376

Start Date

July 16 2019

End Date

September 21 2021

Last Update

October 10 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Indiana University Hospital

Indianapolis, Indiana, United States, 46022